Trial intelligence / Profile preview

Rongliflozin L-pyroglutamic acid plus metformin in type 2 diabetes mellitus

CTR20201770Phase 3Completed

Sponsor
Guangdong Dongyangguang Pharmaceutical
Start
Sep 2020
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of rongliflozin in type 2 diabetes mellitus (T2DM), sponsored by Guangdong Dongyangguang Pharmaceutical. Started Sep 2020; status: completed.

02

Drugs

rongliflozin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on CTR20201770.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20201770.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call